Meeting Coverage:

American Academy of Ophthalmology

AAO: 2019

ABC to Block VEGF-A Isoforms

Show Description +

Charles C. Wykoff, MD, PhD, speaks about KSI-301, a novel antibody biopolymer conjugate (ABC) designed to block VEGF-A isoforms. Dr. Wykoff details the design and results of a phase 1b study that assessed KSI-301 in patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

Posted: 9/11/2019

Up Next

Surgery for Viral Retinitis

J. Fernando Arevalo, MD, PhD, FACS


Iridocorneal Endothelial Syndrome

Lauren S. Blieden, MD

Advanced Diagnostics in Refractive Surgery: Epithelial Mapping and Phakic IOL Sizing

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

Efficacy of Presbyond for the Correction of Presbyopia

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

Autonomous AI in Ophthalmology

Michael D. Abramoff, MD, PhD

CXL for Infectious Keratitis

Farhad Hafezi, MD, PhD, FARVO

MIGS and Medications

Alex Huang, MD

Controlling Wound Healing Following PRK

Farhad Hafezi, MD, PhD, FARVO

A New Anti-VEGF Option

J. Fernando Arevalo, MD, PhD, FACS

PANORAMA Study Data

Rishi P. Singh, MD

Gene Therapy for Wet AMD

Szilard Kiss, MD

ABC to Block VEGF-A Isoforms

Charles C. Wykoff, MD, PhD, speaks about KSI-301, a novel antibody biopolymer conjugate (ABC) designed to block VEGF-A isoforms. Dr. Wykoff details the design and results of a phase 1b study that assessed KSI-301 in patients with wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

Posted: 9/11/2019


Please log in to leave a comment.

More From AAO: 2019 Coverage

A New Anti-VEGF Option

J. Fernando Arevalo, MD, PhD, FACS